NewsSource: EClinCloud

Can Electronic Patient-Reported Outcome (ePRO) Data Be Changed or Not?

3 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

Can ePRO data be changed?


The EMA's recently issued "Guideline on computerised systems and electronic data in clinical trials" draft1 states:

Data clarification procedures initiated by the sponsor or vendor are not acceptable, even with a legitimate justification (regardless of whether they are mentioned in the study protocol)—for example, when a subject discovers that data were not entered correctly.



This aligns with the PRO guidance previously issued by the FDA in 20092, which states:

Sponsors should avoid:

● Complete control of the source file by the sponsor alone;

● Clinical researchers being unable to maintain and ensure the accuracy of ePRO data.


Article illustration

ePRO data cannot be changed unilaterally by the sponsor!

However, it is inevitable that a subject may accidentally tap the wrong option and enter incorrect data; therefore, to ensure that the data are completely accurate, a data correction procedure is essential.

Article illustration


Oops! Tapped the wrong one!

Regulatory guidance and ICH GCP guidelines indicate that sound procedures must be established to allow the investigator to modify data when necessary, such as a Data Change Request (DCR) procedure.


So the question is: when does changing data improve data reliability, and when does it undermine it? For the same patient, is a change made at the time of the assessment as reliable as a change made 1 month after the assessment ends?

Article illustration

Clearly not.


A sound procedure needs to take the following key factors into account:


1

Assess the risk level of the data to be modified.

Low-risk data may include metadata, such as patient identifiers. High-risk data may be clinical outcome values, especially those related to clinical endpoints.

2

Define the process for DCR review.

Working practices for handling low-risk and high-risk data changes should be agreed upon and differentiated according to the risk level of the data. For example, for low-risk data changes, the change can be executed directly at the investigator's request. However, when the data to be changed are classified as high-risk, the sponsor should be promptly alerted so that the sponsor has the opportunity to discuss the required data change jointly with the investigator and the vendor. Such discussions are not intended to control the data, but rather to make every effort to meet regulatory requirements, ensure and maintain data integrity and reliability, and ensure that adequate documentation supports the data change.


3

Maintain an audit trail for data changed through the DCR procedure.

Audit trail records must be created to ensure that data changes made through the DCR procedure are supported by sufficient evidence.

4

Provide instructions for the DCR procedure.

Clear documentation explaining the DCR review procedure should be provided to investigators prior to their participation in the study.

The final decision on whether to change data rests with the study site, and the study site's decision must be fully respected. A rigorous procedure can help the study site fulfill its responsibility for source data. In addition, maintaining data integrity and reliability is also critical to passing regulatory review.

References

1. EMA (2021). Draft guideline on computerised systems and electronic data in clinical trials. https://www. ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-computerised-systems- electronic-data-clinical-trials_en.pdf

2. FDA (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported- outcome-measures-use-medical-product-development-support-labeling-claims

Article source: Signant Health


About EClinCloud


EClinCloud is a healthcare and life-sciences technology company based in China and serving the globe. Driven by science and medicine, and with the mission to "bring effective treatments to patients through technological innovation," it combines digital technology with life-sciences data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping pharmaceutical companies and research institutions in China and abroad improve R&D efficiency, accelerate bringing drugs and medical devices to market, and benefit countless patients.





Article illustration


Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.